Literature DB >> 23000660

Aspirin for primary prevention of CVD: are the right people using it?

Jeffrey J VanWormer1, Robert T Greenlee, Patrick E McBride, Paul E Peppard, Kristen C Malecki, Jianhong Che, F Javier Nieto.   

Abstract

PURPOSE: Aspirin is recommended for the primary prevention of cardiovascular disease (CVD) in adults at high risk, but little is known about sociodemographic disparities in prophylactic aspirin use. This study examined the association between sociodemographic characteristics and regular aspirin use among adults in Wisconsin who are free of CVD.
METHODS: A cross-sectional design was used, and data collected from 2008 to 2010. Regular aspirin use (aspirin therapy) was defined as taking aspirin most days of the week. We found 831 individuals for whom complete data were available for regression analyses and stratified the sample into 2 groups: those for whom aspirin therapy was indicated and those for whom it was not indicated, based on national guidelines.
RESULTS: Of the 268 patients for whom aspirin therapy was indicated, only 83 (31%) were using it regularly, and 102 (18%) of the 563 participants who did not have an aspirin indication were taking it regularly. In the group with an aspirin indication, participants who were older had higher rates of regular aspirin use than younger patients (odds ratio [OR]=1.07; P<.001), and women had significantly higher adjusted odds of regular aspirin use than men (OR=3.49; P=.021). Among those for whom aspirin therapy was not indicated, the adjusted odds of regular aspirin use were significantly higher among older participants (OR=1.07; P<.001) vs their younger counterparts, and significantly lower among Hispanic or nonwhite participants (OR=0.32; P=.063) relative to non-Hispanic whites.
CONCLUSIONS: Aspirin therapy is underused by those at high risk for CVD—individuals who could gain cardioprotection from regular use—and overused by those at low risk for CVD, for whom the risk of major bleeding outweighs the potential benefit. Stronger primary care initiatives may be needed to ensure that patients undergo regular screening for aspirin use, particularly middle-aged men at high CVD risk. Patient education may be needed, as well, to better inform people (particularly older, non-Hispanic whites) about the risks of regular aspirin use that is not medically indicated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000660

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  17 in total

1.  Overall prescription medication use among adults: findings from the Survey of the Health of Wisconsin.

Authors:  Jianhong Che; Kristen C Malecki; Matthew C Walsh; Andrew J Bersch; Vincent Chan; Christine A McWilliams; F Javier Nieto
Journal:  WMJ       Date:  2014-12

2.  Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional health care system.

Authors:  Jeffrey J VanWormer; Aaron W Miller; H Rezkalla
Journal:  WMJ       Date:  2014-10

3.  Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration.

Authors:  Weijun Guo; Wenlin Lu; Yujun Xu; Liansheng Wang; Qin Wei; Qingyun Zhao
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 4.  Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease.

Authors:  Xiao-Ying Li; Li Li; Sang-Hoon Na; Francesca Santilli; Zhongwei Shi; Michael Blaha
Journal:  Am J Prev Cardiol       Date:  2022-06-06

Review 5.  The role of aspirin in the prevention of cardiovascular disease.

Authors:  Sunitha V Ittaman; Jeffrey J VanWormer; Shereif H Rezkalla
Journal:  Clin Med Res       Date:  2014-02-26

6.  In-hospital prognosis of first-ever noncardiogenic ischemic stroke in patients with and without indication for prestroke antiplatelet therapy: Chinese Stroke Center Alliance.

Authors:  Yu-Yuan Xu; Hong-Qiu Gu; Zi-Xiao Li; Yun-Yun Xiong; Qi Zhou; Li-Ping Liu; Xing-Quan Zhao; Yi-Long Wang; Xia Meng; Yong-Jun Wang
Journal:  Ann Transl Med       Date:  2021-04

Review 7.  Aspirin and multiple sclerosis.

Authors:  Sheila Tsau; Mitchell R Emerson; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2015-06-29       Impact factor: 8.775

Review 8.  A systematic review of aspirin in primary prevention: is it time for a new approach?

Authors:  Carlos Brotons; Robert Benamouzig; Krzysztof J Filipiak; Volker Limmroth; Claudio Borghi
Journal:  Am J Cardiovasc Drugs       Date:  2015-04       Impact factor: 3.571

9.  Aspirin Use, Compliance, and Knowledge of Anticancer Effect in the Community.

Authors:  Gurpreet Singh Ranger; Cindy McKinley-Brown; Emma Rogerson; Krystal Schimp-Manuel
Journal:  Perm J       Date:  2019-12-18

10.  A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease.

Authors:  Niki C Oldenburg; Sue Duval; Russell V Luepker; John R Finnegan; Heather LaMarre; Kevin A Peterson; Nicole D Zantek; Ginny Jacobs; Robert J Straka; Karen H Miller; Alan T Hirsch
Journal:  Prev Chronic Dis       Date:  2014-05-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.